Observational studyInternational journal of obesity (2005)2021
Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention.
Observational study in International journal of obesity (2005), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction.Diabetes, obesity & metabolism · 2026Review
- Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan.Endocrinology, diabetes & metabolism · 2026Article
- Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review.Cureus · 2026Review
- Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study.European journal of medical research · 2025Observational
- The Critical Role of Body Composition Assessment in Advancing Research and Clinical Health Risk Assessment across the Lifespan.Journal of obesity & metabolic syndrome · 2025Review
- Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.Diabetes, obesity & metabolism · 2025 · on this mapReview
- GLP-1 and the Neurobiology of Eating Control: Recent Advances.Endocrinology · 2025Review
- Incretin-based therapies for the treatment of obesity-related diseases.npj metabolic health and disease · 2024Review
- Metabolomic Effects of Liraglutide Therapy on the Plasma Metabolomic Profile of Patients with Obesity.Metabolites · 2024Article
- Weight loss with GLP-1 analogues in preparation for transplantation.BMJ case reports · 2024Article
- Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management.Endocrinology and metabolism (Seoul, Korea) · 2024Review
- Dark Data in Real-World Evidence: Challenges, Implications, and the Imperative of Data Literacy in Medical Research.Journal of Korean medical science · 2024Review
- Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.Drug design, development and therapy · 2024Article
- Evaluation of the Effectiveness of Liraglutide on Metabolic Parameters in the Treatment of Obesity.Cureus · 2023Article
- Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery.Biomedicines · 2023Article
- Five-year Weight Loss Maintenance With Obesity Pharmacotherapy.The Journal of clinical endocrinology and metabolism · 2023Article
- Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Marked weight loss on liraglutide 3.0 mg: Real-life experience of a Swiss cohort with obesity.Obesity (Silver Spring, Md.) · 2023Observational
- Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting.Journal of obesity & metabolic syndrome · 2022Article
- Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: A real-world comparative cohort study.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe investigated the efficacy and safety of liraglutide 3 mg daily in combination with diet and exercise 2, 4, and 6 months after initiation in real-world settings in Korea.
methodsPeople first using liraglutide starting in 2018 were recruited from ten sites in Korea. Body weight and body mass index (BMI) were measured after 2, 4, and 6 months and compared with baseline values.
resultsThe full cohort comprised 769 participants: 672 in the 2-month group, 427 in the 4-month group, and 219 in the 6-month group. The baseline mean ± standard deviation of BMI and body weight were 32.2 ± 5.1 kg/m
conclusionsIn real-world settings in Korea, daily treatment with liraglutide 3 mg was associated with clinically meaningful weight loss without serious adverse events.
Indexed as
Identifiers
33473176What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.